Acumen Pharmaceuticals Inc (ABOS)
3.83
+0.02
(+0.52%)
USD |
NASDAQ |
May 22, 10:48
Acumen Pharmaceuticals Cash from Financing (TTM): 158.86M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 158.86M |
| December 31, 2023 | 151.75M |
| September 30, 2023 | 126.80M |
| June 30, 2023 | 3.776M |
| March 31, 2023 | 3.907M |
| December 31, 2022 | |
| September 30, 2022 |
| Date | Value |
|---|---|
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 44.68M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
3.776M
Minimum
Jun 2023
158.86M
Maximum
Mar 2024
81.63M
Average
85.74M
Median
Cash from Financing (TTM) Benchmarks
| Accuray Inc | -3.779M |
| Kezar Life Sciences Inc | 0.484M |
| Akoya Biosciences Inc | 56.82M |
| NovaBay Pharmaceuticals Inc | 1.313M |
| Palatin Technologies Inc | 14.71M |